©2023 AlixPartners, LLP
ABOUT US
For more than 40 years, AlixPartners has helped businesses around the world respond quickly and decisively to their most critical challenges -
circumstances as diverse as urgent performance improvement, accelerated transformation, complex restructuring and risk mitigation.
These are the moments when everything is on the line - a sudden shift in the market, an unexpected performance decline, a time-sensitive deal, a
fork-in-the-road decision. But it's not what we do that makes a difference, it's how we do it.
Tackling situations when time is of the essence is part of our DNA - so we adopt an action-oriented approach at all times. We work in small,
highly qualified teams with specific industry and functional expertise, and we operate at pace, moving quickly from analysis to implementation.
We stand shoulder to shoulder with our clients until the job is done, and only measure our success in terms of the results we deliver.
Our approach enables us to help our clients confront and overcome truly future-defining challenges. We partner with you to make the right
decisions and take the right actions. And we are right by your side. When it really matters.
The opinions expressed are those of the authors and do not necessarily reflect the views of AlixPartners, LLP, its affiliates, or any of its or their respective professionals or clients.
This article Shareholder Value Creation in Japanese Pharmaceuticals ("Article") was prepared by AlixPartners, LLP ("AlixPartners") for general information and distribution on a strictly
confidential and non-reliance basis. No one in possession of this Article may rely on any portion of this Article. This Article may be based, in whole or in part, on projections or forecasts
of future events. A forecast, by its nature, is speculative and includes estimates and assumptions which may prove to be wrong. Actual results may, and frequently do, differ from
those projected or forecast. The information in this Article reflects conditions and our views as of this date, all of which are subject to change. We undertake no obligation to update
or provide any revisions to the Article. This Article is the property of AlixPartners, and neither the Article nor any of its contents may be copied, used, or distributed to any third party
without the prior written consent of AlixPartners.
Shoichiro Ogawa, Partner
sogawa@alixpartners.com
Sho has nearly 30 years of experience in leading and supporting business turnarounds, value
ups, and organizational restructurings in the areas of cultural change, new business, new product
launches, and postmerger integration (PMI) in both business companies and a consulting firm.
Before joining AlixPartners, he led a business at Bristol-Myers Squibb through an organizational
restructuring, a growth strategy execution, a digitalization, and a new product launch. Before
that, he was president of AlconPharma and completed PMI and a reboot of the business. He also
executed organizational changes, business creation, and turnarounds at Abbott, Alcon, AbbVie, and
Janssen. In other engagements, he supported large companies through growth strategies, new
business launches, turnarounds, and PMIs in the healthcare, finance, IT, automobile, trading, and
utility sectors.
Sho has an MBA from Carnegie Mellon University and a master's degree in aerospace engineering
from the University of Tokyo.
Tetsuya Kimura, Partner
tkimura@alixpartners.com
Tetsuya has 20 years of experience as a management consultant, business leader, and privateequity
(PE) investment professional, having supported and led companywide transformation,
business growth, turnarounds, and M&A to improve profitability and value up. Tetsuya has helped
major companies in the telecom, healthcare, retail, financial, and PE industries develop business
strategies, grow their businesses, and conduct turnarounds. His expertise includes M&A and
post-merger integration (PMI), sales force enhancement, productivity improvement, and labor cost
reduction in the PE, telecom, technology, service, and healthcare industries. Previously, he was
with a Japanese midcap PE firm as a deal member; he completed four deals; and he led PMI and
value-up activities as interim chief financial officer/chief strategic officer (CFO/CSO) of the portfolio
company. Tetsuya has a Bachelor of Arts in social psychology from the University of Tokyo.
Jennifer Iarossi, Senior Vice President
jiarossi@alixpartners.com
Jennifer has nearly 20 years of experience as a management consultant and business leader.
Throughout her career, she has provided strategic consulting services for global companies in
industries as diverse as pharmaceutical, financial services, consumer products, metals & mining,
beverages, and heavy equipment. She is also passionate about education, and served as the
director of finance and operations for a group of private schools in the United States.
Jennifer has a Masters of Science in education from Loyola University Maryland and a
Bachelor of Arts from Northwestern University.